Hormonal effects of toremifene in breast cancer patients
| Autor: | S. Kerpel-Fronius, A. Hajba, Matti Grönroos, B. Vincze, I. Számel, J. Mäenpää, I. Hindy, Lauri Kangas, H. Sundquist, S. Eckhardt |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
endocrine system medicine.medical_specialty Hypothalamo-Hypophyseal System medicine.medical_treatment Mammary gland Breast Neoplasms Biochemistry Basal (phylogenetics) Endocrinology Sex hormone-binding globulin Internal medicine Sex Hormone-Binding Globulin Medicine Humans Testosterone Toremifene Thyrotropin-Releasing Hormone Progesterone biology Estradiol business.industry Estrogen Antagonists Luteinizing Hormone Middle Aged Prolactin Hormones Steroid hormone Tamoxifen medicine.anatomical_structure biology.protein Female Follicle Stimulating Hormone business hormones hormone substitutes and hormone antagonists medicine.drug Hormone |
| Zdroj: | Journal of steroid biochemistry. 36(3) |
| ISSN: | 0022-4731 |
| Popis: | The effect of toremifene treatment on the serum levels of sex steroids (estradiol, progesterone, testosterone), FSH, LH, prolactin, TSH, T3, T4 and SHBG was investigated. Basal prolactin level and the “prolactin reserve capacity” of the hypophysis was also studied by the TRH functional test. Steroid hormone receptors were detected in the patients where a tumor biopsy could be obtained. In a randomized trial patients were treated by 60 and 300 mg of toremifene per os, daily. Hormone levels were assayed prior to treatment and at the 2nd, 6th, 8th and 12th week of toremifene therapy. The hormonal effects of toremifene were the most marked at the 2nd and at the 8th week. Estradiol decreased continuously, SHBG increased slightly and the high initial value of basal prolactin level decreased. The TRH induced prolactin release was suppressed by toremifene after an 8-week period. No clinical response-related tendency was found. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|